je.st
news
Home
› Alnylam Receives Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3, An RNAi Therapeutic For The Treatment Of Hemophilia
Alnylam Receives Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3, An RNAi Therapeutic For The Treatment Of Hemophilia
2013-09-04 06:05:53| drugdiscoveryonline News Articles
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the treatment of hemophilia B
Tags: the
of
food
treatment
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||